The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial 8322 View more insights in Professional - Medicine - Hepatology View more figures from University of Western Australia View the page of Dickon Hayne Read the Study · Tools Cite Embed Dickon Hayne discusses the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations. Image courtesy of interviewee. May 29, 2024 Log-in or Sign-up to Faculti Currently viewing this subject insight as a guest. You have insight(s) remaining for this month. Login Sign-up or Subscribe